Search Results
Your search for it matches 15746 pages
Showing 3401 - 3450I’m Living—and Thriving—With Stage IV Non–Small Cell Lung Cancer
A diagnosis, in 2020, of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) was found accidentally. I was 55 at the time and in the best physical shape of my life. I had spent the previous year and a half on a diet and exercise regimen that had rendered me 35 pounds lighter and feeling...
Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor ALL
On October 1, 2021, the CD19-directed chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel was approved for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).1 The product is available only through a restricted program under a Risk Evaluation ...
Expect Questions on Use of Low-Dose Aspirin to Help Prevent Colorectal Cancer
Following a review of new data and additional analyses of previous data concerning colorectal cancer, the U.S. Preventive Services Task Force (USPSTF) “concluded the evidence is inadequate that low-dose aspirin use reduces colorectal cancer incidence or mortality.”1 Consequently, a draft...
Update on the Role of Low-Dose Aspirin in Colorectal Cancer Prevention
Updating its 2016 recommendation on the use of aspirin to prevent cardiovascular disease and colorectal cancer, the U.S. Preventive Services Task Force (USPSTF) issued a draft recommendation statement. It noted the potential harms of daily aspirin, with the most serious being bleeding in the...
The High Price of Pain
According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2019, nearly 247,000 people died from overdoses involving prescription opioids in the United States. According to the CDC, the problem can be broken into three waves. The first began with an increase in prescribing...
Reclaiming a Complicated Genius Who Pursued Cancer With Single-Minded Fury
The Nobel Laureate Otto Warburg was regarded as one of the most significant biochemists of the 20th century, whose exhaustive research led to an understanding of cancer that remains significant to this day. Warburg was also one of the most despised figures in his homeland of Nazi Germany. As a...
Erudition and Assessment on the Longest War in the Modern Era
A little after noon on December 23, 1971, President Richard Nixon entered the White House state dining room. Before 137 esteemed guests from government, science, and industry, he signed the landmark National Cancer Act. It was, in short, a national commitment to conquer cancer. President Nixon...
Early Operation With General Anesthesia
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Last Hug
“Good evening, doc; I wanted to check on you and update you on my mom” read the text message on a late Thursday afternoon. I recognized the sender; it was not uncommon for me to share my cell phone number with patients and their families. Having been a caretaker of my own parents’ medical needs, I...
The History of Medical Oncology in Europe, 1955–1985
In part 1 of this two-part review, we looked at early pioneers in the field of medical oncology in Europe, as well as the development of international cooperative trials and the formation of European oncology societies (see related articles below). In part 2, we explore how the field of medical...
Three Investigators Named Winners of MSK Cancer Center’s 2021 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three recipients of this year’s Paul Marks Prize for Cancer Research. The prize recognizes a new generation of leaders in cancer research who are making significant contributions to the understanding of cancer or are improving the...
Abemaciclib With Endocrine Therapy in Adjuvant Treatment of Early Breast Cancer
On October 12, 2021, abemaciclib was approved for use with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adults with hormone receptor–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki67 score ≥ 20%, as determined by...
Asciminib for Philadelphia Chromosome–Positive Chronic Myeloid Leukemia
On October 29, 2021, the oral kinase inhibitor asciminib was granted accelerated approval for adults with Philadelphia chromosome–positive chronic myeloid leukemia (CML) in chronic phase previously treated with at least two tyrosine kinase inhibitors and regular approval for adults with...
Newer Cancer Therapies Offer Hope but Also May Confer Cardiac Risk
Since many different chemotherapeutic agents have been linked with cardiac adverse events, there is a growing need for strategies for the assessment and mitigation of treatment-induced cardiotoxicity. Moreover, the rapid rise of immunotherapies has added a new dimension to this clinical setting....
Mammen Chandy, MD, FRACP, FRACPA: A Pioneer in India’s Bone Marrow Transplantation Services
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with bone marrow transplant expert Mammen Chandy, MD, FRACP, FRACPA, Director of Tata Medical Center, in Kolkata, India. Dr. Chandy was instrumental in establishing the first sustained bone marrow...
Potential Impact of Nurse Navigation Program in Achieving Equitable Care and Outcomes in Patients With Aggressive Large B-Cell Lymphoma
In a single-institution study reported in the journal Cancer, and reviewed in the September 10, 2021, issue of The ASCO Post, Bei Hu, MD, and colleagues from Levine Cancer Institute/Atrium Health found that the use of a dedicated nurse navigation program aided in producing similar patterns of...
The History of Medical Oncology in Europe, 1955–1985
Our goal with this review of the pivotal years of oncology in Europe is to acknowledge the tremendous contributions of the early leaders in the field and to help young investigators learn from the past to better cope with the inevitable challenges of today and tomorrow. “On ne connaît pas...
COVID-19 Vaccine Requirements for Medicare, Medicaid Facilities, and Employers of 100 or More Staff Released
On November 4, 2021, the Centers for Medicare & Medicaid Services (CMS) issued an interim final rule requiring COVID-19 vaccination of eligible staff at health-care facilities that participate in the Medicare and Medicaid programs, and the Occupational Safety and Health Administration (OSHA)...
ASCO Releases New Guidelines on the Management of Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and CAR T-Cell Therapy
ASCO has released new recommendations for the management of adverse events related to two immunotherapy modalities with increasing application in cancer care—immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy. The recommendations were published as two separate...
Patients With Hormone Receptor–Positive Breast Cancer and Emergent ESR1 Mutations May Benefit From Early Switch to Fulvestrant/Palbociclib
Among patients with hormone receptor–positive breast cancer treated with an aromatase inhibitor plus palbociclib, those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to fulvestrant plus...
Atezolizumab in Adjuvant Therapy for PD-L1–Positive NSCLC
On October 15, 2021, atezolizumab was approved for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non–small cell lung cancer (NSCLC) with PD-L1 expression on ≥ 1% of tumor cells, as determined by a U.S. Food and Drug Administration...
Update on the Incidence of NSCLC: Focus on Need to Implement Widescale Screening
Recent articles in JAMA Oncology focused on lung cancer and screening strategies. Apar Kishor Ganti, MD, MS, of the University of Nebraska Medical Center, Omaha, and colleagues provided updated data on non–small cell lung cancer (NSCLC) incidence, prevalence, and stage through 2017.1 Sylvia K....
Use of Adjuvant Chemotherapy in Older Patients With Pancreatic Cancer and Its Effect on Overall Survival
In a study reported in JAMA Oncology, Mehtsun et al found patterns of increasing use of adjuvant chemotherapy over time among patients aged ≥ 80 years undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. In addition, they found that use of adjuvant chemotherapy was associated...
Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma
On November 17, 2021, the immunotherapeutic agent pembrolizumab was granted approval for adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy or nephrectomy and resection of metastatic lesions.1 Supporting Efficacy Data...
Low-Dose Computed Tomography: A Window Into Early Lung Disease?
Lung health in adults has traditionally been defined as the absence of disease, but it may be time to rethink this paradigm, according to Ravi Kalhan, MD, MS, Director of the Northwestern Asthma and Chronic Obstructive Pulmonary Disease (COPD) Program at Northwestern University Feinberg School of...
Big Data and Vulnerable Populations: Addressing the Gap in Lung Cancer Screening
Recent advances in medical imaging have led to more accurate detection and management of early thoracic diseases such as lung cancer, chronic obstructive pulmonary disease (COPD), and cardiovascular disease—three of the top four leading causes of death in the United States. Unfortunately, if not...
Expert Point of View: Nabil F. Saba, MD, FACP
“It’s becoming more and more clear that increasing the cytotoxic effect of treatment and expecting to get a better outcome is an approach of the past,” said Nabil F. Saba, MD, FACP, the Lynne and Howard Halpern Chair in Head and Neck Cancer Research, Professor and Vice Chair ofHematology and...
Radiation Therapy for HPV-Related Oropharyngeal Squamous Cell Carcinoma: Prospects and Controversies
In the treatment of patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma, neither cancer outcomes nor measurable quality of life have yet been shown to differ between surgery- and radiotherapy-based approaches, according to Sue S. Yom, MD, PhD, FASTRO, Professor of ...
Cleveland Clinic Researcher Receives NIH Director’s Pioneer Award
Michaela Gack, PhD, Scientific Director of Cleveland Clinic’s Florida Research and Innovation Center, has received a National Institutes of Health (NIH) Director’s Pioneer Award to support her research toward the development of broad-spectrum antiviral drugs. The grant is part of NIH’s High-Risk,...
Expert Point of View: Nabil F. Saba, MD, FACP
“Immunotherapy is now the standard of care in the recurrent metastatic setting,” said Nabil F. Saba, MD, FACP, Director of Head and Neck Oncology at Emory University and a specialist in immunotherapy for head and neck cancer. “However, we’re still struggling with the question of which immunotherapy ...
Optimizing the Use of Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Cancer
The management of recurrent and/or metastatic head and neck cancer is complex. Historically, patients with squamous cell carcinoma of the head and neck with local or regional recurrence were considered for salvage surgery or reirradiation (in high-volume centers or centers of expertise), with an...
Applying Research Data to Clinical Practice in Managing Head and Neck Cancer
The 2021 Winship Cancer Institute of Emory University Symposium: Updates in the Management of Head and Neck Cancer explored current paradigms for the multidisciplinary treatment of head and neck cancer.1 Moderated by Nabil F. Saba, MD, FACP, the Lynne and Howard Halpern Chair in Head and Neck...
Society for Integrative Oncology Focuses on the Science of Living Well With Cancer
Guest Editor’s Note: With the easing of some COVID-19 restrictions, the Society for Integrative Oncology (SIO) held its 2021 international conference in a hybrid format. It focused on the science of living well with cancer, challenges in designing integrative oncology research, and the role of...
To Elect or Forgo Radiation Therapy: An Informed Decision for Patients With Breast Cancer
Advances intreating breast cancer “increasingly create opportunities to consider where radiation therapy might safely be omitted,” Reshma Jagsi, MD, DPhil, told participants at the 2021 Lynn Sage Breast Cancer Symposium.1 “But, I would encourage us,” she continued, “not to assume that women who...
How Medical Oncology Came to Be
For many, the way things are when you learn about them is assumed to be the way things have always been. For example, antibiotics are wonderful—but if you were practicing medicine when penicillin was discovered, it would have seemed like a miracle. For most of us, there have always been chemical...
Establishing a Health Equity Report Card to Eradicate Disparities in Cancer Care
Although enormous progress over the past 50 years in every aspect of cancer care, including prevention, screening, chemotherapy, targeted therapy, surgery, radiation therapy, and supportive care, has resulted in increases in lives saved—from 3 million in 1971 to 16.9 million in 2019—the burden of...
Single-Cell Spatial Analysis May Help to Predict Response to Neoadjuvant Atezolizumab in Patients With Triple-Negative Breast Cancer
A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab to chemotherapy as...
Researchers Identify Significant Differences in Tumor Characteristics Between Younger and Older Patients With Cancer
Investigators at Weill Cornell Medicine have identified significant differences in the molecular characteristics of tumors from younger and older patients with cancer across several cancer types. Their research, published by Shah et al in Cell Reports, suggests that cancer treatment could...
Molecular Tumor Profiling May Improve Treatment Matching for Patients With Metastatic Breast Cancer
The use of multigene sequencing and SNP array as a therapeutic decision tool improved the outcomes of patients with metastatic breast cancer if the patients carried alterations classified in the I/II tiers of the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT), according to...
I-SPY2 Study Finds Tumor Biology Is a More Significant Factor Than Race in Predicting Response to Breast Cancer Treatment
Data analysis from the I-SPY2 clinical trial found that among women with high-risk breast cancer, race did not significantly affect several key measures of breast cancer treatment outcomes, including pathologic complete response (pCR) and event-free survival. The study, which is being presented by...
Expert Point of View: Adam M. Brufsky, MD, PhD
Adam M. Brufsky, MD, PhD, Professor of Medicine at the University of Pittsburgh School of Medicine and Co-Director of the Comprehensive Breast Cancer Center, commented on the KEYNOTE-355 final analysis1 for The ASCO Post. “We now have a drug with full approval of the U.S. Food and Drug...
KEYNOTE-355 Final Analysis Reveals Survival Benefit With Pembrolizumab in Triple-Negative Breast Cancer
The final overall survival results from the KEYNOTE-355 study showed a statistically significant 27% reduction in the risk of death for patients with metastatic triple-negative breast cancer whose tumors were strongly positive for PD-L1, defined as a combined positive score (CPS) of at least 10 and ...
COVID-19 Vaccination: Patients With Multiple Myeloma May Lack T-Cell Response
Patients with multiple myeloma lacking an antibody response to COVID-19 vaccination may also fail to mount a T-cell response, researchers from the Icahn School of Medicine at Mount Sinai have reported. This scenario seemed to be most common among patients actively treated with anti-CD38 and...
Next-Generation Sequencing of Bone Marrow DNA to Predict Relapse Following CAR T-Cell Therapy in Patients With ALL
Next-generation sequencing of bone marrow samples from pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel was more accurate in predicting relapse than flow cytometry and monitoring of B-cell aplasia, according to the results from a study by...
To Elect or Forgo Radiation Therapy: An Informed Decision for Patients With Breast Cancer
Advances in treating breast cancer “increasingly create opportunities to consider where radiation therapy might safely be omitted,” Reshma Jagsi, MD, DPhil, told participants at the 2021 Lynn Sage Breast Cancer Symposium.1 “But, I would encourage us,” she continued, “not to assume that women who...
Keith T. Flaherty, MD, on Results From the DREAMseq Trial
Invited discussant of the phase III DREAMseq trial, Keith T. Flaherty, MD, said the findings still leave room for nuanced decision-making.1 Dr. Flaherty is Professor of Medicine at Harvard and Director of the Henri and Belinda Termeer Center for Targeted Therapy at the Massachusetts General...
DREAMseq Trial: In Advanced Melanoma With BRAF Mutations, Start With Immunotherapy
In the treatment of patients with advanced melanoma containing BRAF mutations, initial treatment with an immunotherapy combination achieved superior overall survival compared with targeted therapy in the phase III DREAMseq trial, also known as the ECOG-ACRIN EA6134 trial. The results were reported ...
Effect of the COVID-19 Pandemic on Cancer Imaging
Significant decreases in computed tomography (CT) imaging for cancer persisted even after the peak of the COVID-19 pandemic in 2020—delaying diagnosis and treatment and raising the possibility of more advanced cancers and poorer outcomes for patients, according to a study presented at the...
Aditya Bardia, MD, MPH, Comments on Findings From monarchE
The invited discussant of monarchE,1 Aditya Bardia, MD, MPH, Director, Breast Cancer Research, and Associate Professor of Medicine, Harvard Medical School, commented: “Based on a hazard ratio of 0.69 for invasive disease–free survival, the results are statistically significant and clinically...
Long-Term Follow-up of monarchE: Benefit of Abemaciclib Plus Endocrine Therapy Maintained in Early High-Risk Breast Cancer
Longer-term follow-up of the global phase III monarchE trial showed an increasing benefit for adding abemaciclib to endocrine therapy in the adjuvant treatment of early high-risk hormone receptor–positive, HER2-negative breast cancer, regardless of Ki67 index. The latest findings were reported at a ...
